The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients
Open accessAbstract
// Rui Shi 1 , Pei-Yin Wang 2 , Xin-Yi Li 4 , Jian-Xin Chen 1 , Yan Li 1 , Xin-Zhong Zhang 2 , Chen-Guang Zhang 3, 6 , Tao Jiang 5 , Wen-Bin Li 1, * , Wei Ding 3, 6 , Shu-Jun Cheng 1, * 1 Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China 2 Department of Neurosurgery, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang Medical University, Henan, China 3 Beijing Key Laboratory for Tumor Invasion and Metastasis, Cancer Institute of Capital Medical University, Beijing, China 4 University of South Florida, Tampa, FL, USA 5 Department of Neurosurgery, Tiantan Hospital, Capital Medical University, Beijing, China 6 Department of Biochemistry, Molecular Biology Capital Medical University, Beijing, China * These authors have contributed equally to this work Correspondence to: Wen-Bin Li, e-mail: liwenbin@ccmu.edu.cn Shu-Jun Cheng, e-mail: chengshj@cae.cn Keywords: extracellular vesicles, cerebrospinal fluid, hsa-mir-21, glioma, cancer prognosis Received: March 04, 2015 Accepted: July 27, 2015 Published: August 10, 2015 ABSTRACT Glioma is a most common type of primary brain tumors. Extracellular vesicles, in the form of exosomes, are known to mediate cell–cell communication by transporting cell-derived proteins and nucleic acids, including various microRNAs (miRNAs). Here we examined the cerebrospinal fluid (CSF) from patients with recurrent glioma for the levels of cancer-related miRNAs, and evaluated the values for prognosis by comparing the measures of CSF-, serum-, and exosome-contained miR-21 levels. Samples from seventy glioma patients following surgery were compared with those from brain trauma patients as a non-tumor control group. Exosomal miR-21 levels in the CSF of glioma patients were found significantly higher than in the controls; whereas no difference was detected in serum-derived exosomal miR-21 expression. The CSF-derived exosomal miR-21 levels correlated with tumor spinal/ventricle metastasis and the recurrence with anatomical site preference. From additional 198 glioma tissue samples, we verified that miR-21 levels associated with tumor grade of diagnosis and negatively correlated with the median values of patient overall survival time. We further used a lentiviral inhibitor to suppress miR-21 expression in U251 cells. The results showed that the levels of miR-21 target genes of PTEN, RECK and PDCD4 were up-regulated at protein levels. Therefore, we concluded that the exosomal miR-21 levels could be demonstrated as a promising indicator for glioma diagnosis and prognosis, particularly with values to predict tumor recurrence or metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA-21 Is an Antiapoptotic Factor in Human Glioblastoma Cells
Chan, J. A., Krichevsky, A. M., & Kosik, K. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0137 · Cited by 2,557
Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function
Zhang, J., Li, S., Li, L., Li, M., Guo, C., Yao, J., & Mi, S. (2015) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2015.02.001 · Cited by 1,901
MicroRNA 21 Promotes Glioma Invasion by Targeting Matrix Metalloproteinase Regulators
Gabriely, G., Wurdinger, T., Kesari, S., Esau, C. C., Burchard, J., Linsley, P. S., & Krichevsky, A. M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00479-08 · Cited by 888 · cited 1×
“The level of miR-21 was up-regulated in the tissue of higher grade gliomas (grade III and glioblastomas) compared with that of the non-neoplastic brain tissues and promote cell survival and invasion in glioblastoma cells [11, 12] A range of target genes have been identified for miR-21, among which, PTEN [13], RECK4 [1…”
BackgroundTurturici, G., Tinnirello, R., Sconzo, G., & Geraci, F. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00228.2013 · Cited by 483
Extracellular vesicles: emerging targets for cancer therapy
Vader, P., Breakefield, X. O., & Wood, M. J. A. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.03.002 · Cited by 421
Akers, J. C., Ramakrishnan, V., Kim, R., Skog, J., Nakano, I., Pingle, S., Kalinina, J., Hua, W., Kesari, S., Mao, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078115 · Cited by 337
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Franklin, R. A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.659 · Cited by 314
Teplyuk, N. M., Mollenhauer, B., Gabriely, G., Giese, A., Kim, E., Smolsky, M., Kim, R. Y., Saria, M. G., Pastorino, S., Kesari, S., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos074 · Cited by 302
Proteogenomic analysis reveals exosomes are more oncogenic than ectosomes
Keerthikumar, S., Gangoda, L., Liem, M., Fonseka, P., Atukorala, I., Ozcitti, C., Mechler, A., Adda, C. G., Ang, C.-S., & Mathivanan, S. (2015) · Oncotarget · doi:10.18632/oncotarget.3801 · Cited by 270
Helseth, R., Helseth, E., Johannesen, T. B., Langberg, C. W., Lote, K., Rønning, P., Scheie, D., Vik, A., & Meling, T. R. (2010) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2010.01350.x · Cited by 215
Cited by
Doyle, L., & Wang, M. (2019) · Cells · doi:10.3390/cells8070727 · Cited by 3,236
Exosomes in cancer development, metastasis, and immunity
Zhang, L., & Yu, D. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.004 · Cited by 870
Advances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662
The biology, function, and applications of exosomes in cancer
Liu, J., Ren, L., Li, S., Li, W., Zheng, X., Yang, Y., Fu, W., Yi, J., Wang, J., & Du, G. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.001 · Cited by 561
Self-citationClinical implications of intratumor heterogeneity: challenges and opportunities
Ramón y Cajal, S., Sesé, M., Capdevila, C., Aasen, T., De Mattos-Arruda, L., Diaz-Cano, S. J., Hernández-Losa, J., & Castellví, J. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01874-2 · Cited by 514
MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression
Teng, Y., Ren, Y., Hu, X., Mu, J., Samykutty, A., Zhuang, X., Deng, Z., Kumar, A., Zhang, L., Merchant, M. L., et al. (2017) · Nature Communications · doi:10.1038/ncomms14448 · Cited by 408
Exosomal noncoding RNAs in Glioma: biological functions and potential clinical applications
Cheng, J., Meng, J., Zhu, L., & Peng, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01189-3 · Cited by 319
Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer
Liu, Q., Yu, Z., Yuan, S., Xie, W., Li, C., Hu, Z., Xiang, Y., Wu, N., Wu, L., Bai, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14369 · Cited by 258
Self-citationXia, X., Wang, Y., Huang, Y., Zhang, H., Lu, H., & Zheng, J. C. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101694 · Cited by 202
Abels, E. R., Maas, S. L. N., Nieland, L., Wei, Z., Cheah, P. S., Tai, E., Kolsteeg, C.-J., Dusoswa, S. A., Ting, D. T., Hickman, S., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.036 · Cited by 199
The role of MiRNA-21 in gliomas: Hope for a novel therapeutic intervention?
Aloizou, A.-M., Pateraki, G., Siokas, V., Mentis, A.-F. A., Liampas, I., Lazopoulos, G., Kovatsi, L., Mitsias, P. D., Bogdanos, D. P., Paterakis, K., et al. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.11.001 · Cited by 69
Mafi, A., Rahmati, A., Babaei Aghdam, Z., Salami, R., Salami, M., Vakili, O., & Aghadavod, E. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00354-4 · Cited by 56
Tang, C., Gu, Y., Wang, H., Wu, H., Wang, Y., Meng, Y., Han, Z., Gu, Y., Ma, W., Jiang, Z., et al. (2018) · Epilepsy Research · doi:10.1016/j.eplepsyres.2018.05.001 · Cited by 50
Nedaeinia, R., Sharifi, M., Avan, A., Kazemi, M., Nabinejad, A., Ferns, G. A., Ghayour-Mobarhan, M., & Salehi, R. (2017) · Tumor Biology · doi:10.1177/1010428317692261 · Cited by 47
Müller, M., Kuiperij, H. B., Versleijen, A. A. M., Chiasserini, D., Farotti, L., Baschieri, F., Parnetti, L., Struyfs, H., De Roeck, N., Luyckx, J., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160038 · Cited by 41
Unraveling the impact of miR-21 on apoptosis regulation in glioblastoma
Shaikh, M. A. J., Altamimi, A. S. A., Afzal, M., Gupta, G., Singla, N., Gilhotra, R., almalki, W. H., Kazmi, I., Alzarea, S. I., Prasher, P., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155121 · Cited by 37
Jiang, G., Mu, J., Liu, X., Peng, X., Zhong, F., Yuan, W., Deng, F., Peng, X., Peng, S., & Zeng, X. (2020) · Scientific Reports · doi:10.1038/s41598-020-61155-3 · Cited by 33
Prieto-Fernández, E., Aransay, A. M., Royo, F., González, E., Lozano, J. J., Santos-Zorrozua, B., Macias-Camara, N., González, M., Garay, R. P., Benito, J., et al. (2019) · Theranostics · doi:10.7150/thno.31502 · Cited by 28
Monteiro-Reis, S., Carvalho-Maia, C., Bart, G., Vainio, S. J., Pedro, J., Silva, E. R., Sales, G., Henrique, R., & Jerónimo, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063267 · Cited by 21
Glioblastoma exosomes reprogramming the tumor microenvironment and evading therapeutic challenges
Tatode, A., Premchandani, T., Chaudhary, A. A., Ali, M. A. M., Qutub, M., Taksande, J., Khan, R., Hussain, U. M., & Umekar, M. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11526-2 · Cited by 3
Metadata
- Authors
- Shi, R., Wang, P.-Y., Li, X.-Y., Chen, J.-X., Li, Y., Zhang, X.-Z., Zhang, C.-G., Jiang, T., Li, W.-B., Ding, W., & Cheng, S.-J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-08-10
- Volume
- 6
- Issue
- 29
- Pages
- 26971-26981
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2107705644
- Cited by
- 285
- References
- 25
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.